Kadar Fibrinogen Pada Penderita Penyakit Jantung Koroner yang Dilakukan Angiografi

  DAFTAR PUSTAKA 1. Risk score profiles. Framingham Heart Study ( Internet). 2012.

  (cited 2012 Feb 5) Available from:

   2. Silvia Loraine, 2006 a. Penyakit Aterosklerotik Koroner.

  Patofisiologi Konsep Klinis Proses-Proses Penyakit Volume I. Edisi

  VI. Penerbit Buku Kedokteran EGC Jakarta hal 576-612

  3. Price SA. Prosedur diagnostik penyakit kardiovaskular. Dalam: Wijaya C editor. Patofisiologi konsep klinis proses-proses penyakit.

  Edisi 4. Jakarta: Penerbit Buku Kedokteran EGC; 1994: 515-523

  4. Hollinger I. Mitinach A. Cardiac catheterization and other radiographic examination. Pediatric Cardiac Anesthesia. 4. ed Lippincott Williams and Walkins 2005; 7: 112-135

  5. Trianti M, Xanthos T, Lacovidou N, et al. Relationship between individual cardiovascular risk factors and localization of coronary atherosclerotic lesions. Heart and Lung: The journal of acute and critical care, 2010

  6. Deitcher SR, Rodgers GM.Trombosis and Antitrombotic Therapy.

  In: Greer JP, Foerster J, Lukens JN, et al. Wintrobe”s Clinical

  th

  Hematology. 11 ed Lippincott Williams and Wilkins. USA. 2004: 1714-18

  7. McKay J, George AM, Shantu M. Kurt G. The atlas of Heart Disease and Stroke. WHO.Geneva; 2004

  8. Hasan R. Obat – obat anti agregasi trombosit pada PJK, UPF Ilmu Penyakit Dalam FK – USU / RSUP H. Adam Malik Medan, 1997 : 1

• – 5

  9. Irmalita. Infark Miokard. Dalam buku ajar Kardiologi. FKUI. Jakarta, 1996:173-77

  10. Setiabudy R. Patofisiology thrombosis; dalam hemostasis dan thrombosis. Patologi Klinik FKUI/ RSCM. Jakarta, 1992:26-35

  11. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology, and determinants. Hemostasis Thrombosis and Vascular Biology.

  University of Medicine Birmingham, 2003: 712-23

  12. Harjai KJ. Potential New Cardiovascular Risk Factors: Left Ventricular Hyperthrophy, Homocystein, Lipoprotein (a), Triglycerides, Oxidative Stress and Fibrinogen. Annal of Internal Medicine, 1999; 131 (5): 376-86 13. Tarrallo P. Reference Limit of Plasma Fibrinogen. Eur. J. Clin.

  Chem. Clin. Biochem, 1992; 30(11): 745-51

  14. Stone MC, Thorp Jm. Plasma fibrinogen a major coronary risk factor; J Roy Coll Gen Prac 1985: 565-9

  15. Cooper J, Douglas AS. Fibrinogen Levels as a Predictor of Mortality in Survivors of Myocardial Infarction. Fibrinolysis Vol.5 no.2,1991: 105-8

  16. Lee AJ. Fibrinogen in Relation to Personal History of Prevalent Hypertension, Diabetes, Stroke, Intermittend Claudication,

  Coronary Heart Disease and Family History, The Scottisth Heart Health Study. British Heart Journal, 1993; 69: 338-42

  17. Jastrzebska M., Foltynska A., Tourbus-Lisiecka B., Chelstowski K., Piechul-Mroz J. et al. Fibrinogen and von Willebrand Factor Levels in Relation to Lipid Profile and Blood Presure in Children Whose Fathers Have a History of Premature Myocardial Infarction. Polish Heart Journal, 2002; 6(5)

  18. Green David, Foiles Nancy, Chan Cheeling et al. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: The CARDIA Study. Atherosclerosis 202 (2009) 623 – 631

  19. Thompson GR. A handbook of Hyperlipidemia. London: Merc & Co.1990

  20. Fargenbaum J. Aterosclerosis 2003. Available from

  

  21. Widjaya DJ. Perkembangan penyelidikan Mutakhir Faktor Risiko Stroke. Kumpulan Makalah Simposium Continuing Medical

  th

  Education The 6 Perdossi Course on Stroke. Jakarta.1999

  22. Marcovina SM, Koschinsky ML. Lipoprotein (a): Structure, Measurement and Clinical Significance In: Rifai N, Warnick RG, Dominiczak MH. Handbook of Lipoprotein Testing 2009. P: 283 – 313 23. Karniawati M, Lipoprotein (a). Informasi Laboratorium Prodia. 2000.

  P: 1- 4

  24. Packard RR, Libby P. Inflamation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin chem..

  2008, p: 24 – 28

  25. Hansson GK. Inflammation , atherosclerosis and coronary artery disease. N engl J Med. 2005.p: 1685 – 95

  26. Hunziker PR. Bedside quantification of atherosclerosis severity for cardiovascular risk stratification: a prospective cohort study, J Am Coll Cardiol. 2002; 39:702-9

  27. Feskens EJ, Kromhouts D. Glucosa tolerance and risk of cardiovascular disease: the Zutphen study. J Clin Epidemiol. 2002; 45: 1327 – 34 28. Jennings PE. The mechanism of diabetic macroangiopathy.

  Diabetographia. International Medical Publication 2003; 11: 4 – 6 29. Osterud B, Bjorklid E. Role of monocytes in atherogenesis.

  Department of Biochemistry, Institude of Medical biology, Faculty of Medicine University of Tiomso, Norway. 2003. P: 1077 – 8

  30. Hills L.D. and Braundwald; E: Coronary - artery Spasm. N. Engl. J.

  Med 2001; 299: 695

  31. Davies, M. J. Intramyocardial platelets aggregation in patient with unstable angina suffering sudden ischemic cardiac death.

  Circulation. 2001; 73: 418

  32. Fahey VA and Riegel BJ: Advances in diagnostic testing for vascular disease, Cardiovasc Nurs 25(3). 1999: 13 – 8

  33. Mannering D, Bennett ED, Ward DE, Dawkins K, Dancy M, Valantine H, et al. Accurate detection of triple vessel disease in patients with exercise induced ST segment depression after infarction. Br Heart J; 1987:57:133-8

  34. Goodnight SH., Hathaway WE. Abnormalities of fibrinogen In Disorders of Hemostasis and Trombosis A Clinical Guide. Ed. 2. Mc Graw Hill companies Ne 2001; 18: 175 – 78

  35. Greenberg CS., Orthner CL. Blood Coagulation and Fibrinolysis in

  th

  Wintrobe’s Clinical Haematology 9 ed. Lippincott Williams & Wilkins. Philadelphia, 2002:495

  36. Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H. Hematology: Basic principles and practice. 5rd ed.

  Philadelphia 2007: Churcill Livingstone Inc. p: 1827, 2046-7

  37. Mosesson MW. Fibrinogen & Fibrin Polymerization: The Binding Events That Accompanya Fibrin Generation and Fibrin Clot Assembly. Blood Coagulation Fibrinolisis. 1997. P : 257 - 67

  38. Giangrande PLF. Fibrinogen Deficiency 2010, available at:

  

  39. Ziedins KB, Orfeo T, Jenny NS, et al. Blood Coagulation and Fibrinolisis. In: Greer JP, et al, (Eds). Wintrobe’s Clinical

  th

  Haematology, 11 ed. Lippincott Williams & Wilkins, 2004: 677-774

  40. Browse MS. Fibrinogen Medical Encyclopedia, Verimed heathcare Network 2011

  41. Cote HCF, Lord ST, Pratt KP.y – Chain Dysfibrinogemias: Molecular Structure – Function Relationship of naturally Occuring Mutations in the y Chain of Human Fibrinogen. The Journal Of The American Society of Haematology, Oct 1998:92(7)

  42. Roberts HR, Monroe DM, Hoffman M. Molecular Biochemistry Of The Coagulation Factors and Pathways of Haemostasis. In: Beutler

  E, Litchman MA, Coller BS, Kipps TJ, Eds. Williams Haematology,

  th

  6 ed. New York: Mc Graw Hill, 2001: :1423-5

  43. Richard A, Mc Person. Specific Protein. In: Davey FR, Nakamura RM Eds. Henry JB. Clinical Diagnosis by Laboratory Methods

  th

  Philadelphia, 19 ed WB Saunders Company, 1996;237-240

  44. Ernst E, Resch KL. Fibrinogen as a Cardiovascular Risk factor A Meta – Analysis and Review of the Literature. European heart journal 1993; 118: 956-63

  45. Stecc JJ, Silbershatz H. Association of Fibrinogen with Cardiovascular Risk Faktor and Cardiovascular diseases In the Framingham Offspring Population. Circulation 2000; 1634-38

  46. Smith EB. Fibrinogen, fibrin and fibrin degradation product inrealition to atherosclerosis. Clin Haematol 1986; Vol 15: 355-70

  47. Ross, Epstein FH. Atherosclerosis an inflammatory disease. N Engl J Med. 1999.p: 115-26

  48. Kannel WB, Wolf PA, Castell, Agostino RB. Fibrinogen and risk of cardiovascular diseases. The Framingham Study In The Journal of the American Medical Association 1987; Vol.258: 1-15

  49. Nito I. Correlation between Cortisol level and myocardial infarction mortality among ICCU patients during first seven days in hospital.

  Acta Medica Indosianna, 2004: 8-10

  50. Frohlich M, Sund M. Independent association of various smoking characteristics with markers of systemic inflammation in men In European Heart Journal 2003; Vol 24: 1365-72

  51. Martin AS, Steininger CA, Koepke J. Routine and special laboratory evaluation of coagulation In Clinical hematology. Principles, Procedurs, Correlation Ed 2. Lippincott Philadelphia New York 1998; 49: 639-40

  52. Wood S. What’s “ normal ? “ Little consensus on CAD extent, severity among Ontario angiographers 2011

  53. Bayes-Ganis A, maleo J, Santalo M, Oliver A, Guindo J, Badimon L, et al. Early diagnostic marker of Coronary ischaemia in patients with chest pain. Am Heart J 2000; 140: 379-84

  54. Greenberg CS, Orthner CL. Blood Coagulation and Fibrinolysis in

  th

  Wintrobe’s Clinical Hematology 9 ed.Lippincott Williams and Wilkins. Philadelphia,1999: 684-764

  55. Gabay C. and Kushner I. Acute-Phase Proteins and other Systemic Responses to Inflammation. The New England Journal of Medicine, 1999; 340(6): 448-454

  56. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P.C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME study. Arterioscler Thromb Vasc Biol 2003;23: 1255-1261 57. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E. Impact of

  C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.

  58. Koh SCL, Biol C, Mibiol. Diagnostic Approach to Hypercoagulation

  th

  and enhanced Fibrynolisis presented at the 8 International Congres of The Asian Society of Clinical Pathology and Laboratory Medicine ( ASCPALM) 29 November 29, 2000 :3-4